Photo by nci from unsplash
TP53 mutations are associated with significant poorer outcomes in mantle cell lymphoma (MCL), and new treatment strategies are highly warranted. Lenalidomide has shown high efficacy in MCL; however, there is… Click to show full abstract
TP53 mutations are associated with significant poorer outcomes in mantle cell lymphoma (MCL), and new treatment strategies are highly warranted. Lenalidomide has shown high efficacy in MCL; however, there is no knowledge of its effect on TP53 mutated cases. In this study, we show that the addition
Keywords:
plus bendamustine;
lenalidomide plus;
mantle cell;
tp53;
tp53 mutations;
cell lymphoma
Journal Title: Haematologica
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haematologica
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!